Li Jia, Ph.D.
Dr. Jia serves as the Biomedical Informatics Manager in the Clinical Trials Operations and Informatics Branch (CTOIB), where she focuses on streamlining clinical trial systems, optimizing processes, and implementing emerging technologies to enhance research and other initiatives.
Dr. Jia leads cybersecurity efforts across CTEP system teams, monitoring and addressing system vulnerabilities and refining security incident response processes. As she leads CTEP systems cloud migration efforts, she oversees the phased transition of CTEP systems to the AWS cloud in the manner of cost-efficiency and security compliance. Additionally, she provides oversight and planning of the CTEP Enterprise System and Identity Proofing and Verification processes.
Dr. Jia worked at the NCI as a scientist for nine years, where she was heavily involved in diverse research studies, including translational medicine, and contributed significantly to cancer immunotherapy clinical trials. With a robust background in computational biology for cancer research, Dr. Jia has developed expertise in data analysis, data management, and data science. Her professional interests lie in applying machine learning (ML) and Artificial Intelligence (AI) models within CTEP to automate and optimize some system processes, as well as advancing data analysis, standardization and management for clinical trial data.
Selected Publications
Lowery FJ, et al. Molecular signature of antitumor neoantigen-reactive T cells from metastatic human cancers. Science (2022) DOI: 10.1126/science.abl5447.
Krishna S, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science (2020) DOI: 10.1126/science.abb9847
Ahmadzadeh M, Pasetto A, Jia L, et al. Tumor-infiltrating human CD4+ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. Science Immunology (2019) DOI: 10.1126/sciimmunol.aao4310
Doran SL, et al. T-Cell receptor gene therapy for human papillomavirus-associated epithelial cancers: A First-in-Human, phase I/II study. J Clin Oncol. (2019) DOI: 10.1200/JCO.18.02424
Gara S, Jia L, et al. Germline HAPB2 in Familial Papillary Thyroid Cancer. New England Journal of Medicine (2015) DOI: 10.1056/NEJMc1511631.